Maas BiolAB Receives Fort Detrick Technology Transfer Initiative Grant for Cyclosporin Neuroprotection
ALBUQUERQUE, N.M.–(BUSINESS WIRE)–April 25, 2006 – The Fort Detrick Technology Transfer Initiative (FDTTI) managed by the Maryland Technology Development Corporation (TEDCO) has awarded $50,000 to Maas BiolAB, LLC to continue development of its cyclosporin neuroprotection products. Funding for the FDTTI is provided by the United States Congress.
Maas BiolAB, LLC is developing proprietary cyclosporin formulations for the treatment of battlefield traumatic brain injury and nerve agent exposure. This FDTTI grant will speed development of these cyclosporin formulations, which are being tested at the Walter Reed Army Institute of Research (WRAIR) in Silver Spring, Maryland, by Drs. Richard A. Bauman and Joseph B. Long of the Division of Military Casualty Research, Department of Polytrauma and Resuscitation. Pre-clinical trials at WRAIR by Drs. Bauman and Long have demonstrated that cyclosporin reduces brain damage caused by nerve agents and trauma. Neurohistological outcomes, spatial memory and learning rates have been improved in animal models when cyclosporin is used.
The FDTTI program is designed to support the development of private sector company technologies that support the medical needs of the United States Army. TEDCO works closely with the U.S. Army Medical Research and Materiel Command (USAMRMC) to maintain awareness of pipeline medical defense technologies and to help transition successful projects into funding by the U.S. Army.
Dr. Marcus Keep, Maas BiolAB CEO, and neurosurgeon, stated: “We are grateful and honored to be one of the emerging medical defense companies chosen by TEDCO for funding in 2006. This award will guide our cyclosporin neuroprotection products toward the hands of medics and doctors to give effective battlefield treatments to protect the brains of wounded soldiers.”
About The Maryland Technology Development Corporation (TEDCO)
The Maryland Technology Development Corporation (TEDCO), an independent entity, was established by the Maryland General Assembly in 1998 to facilitate the creation of businesses and foster their growth. TEDCO’s role is to be Maryland’s leading source of funding for seed capital and entrepreneurial business assistance for technology transfer and development programs. TEDCO connects emerging technology companies with federal laboratories, research universities, business incubators and specialized technical assistance. For the second consecutive year, TEDCO was recognized as the most active “early/seed stage investor in the nation” in the July 2005 issue of Entrepreneur Magazine. For more information on TEDCO, visit www.MarylandTEDCO.org.
About Maas BiolAB, LLC
Maas BiolAB, LLC is a privately held pharmaceutical corporation based in Albuquerque, NM, USA, developing cyclosporin neuroprotection drugs for brain diseases. Maas BiolAB, LLC, in participation with its subsidiary NeuroPharma AB, is developing NeuroSTAT(TM), a proprietary non-toxic intravenous cyclosporin formula for acute neurological indications from traumatic brain injury to neurotoxin exposure. Maas BiolAB, LLC, in participation with its subsidiary Maas Biolab, Inc, is developing Mitogard(TM), a proprietary cyclosporin formula designed for delivery into the cerebrospinal fluid to treat neurodegenerative diseases, including amyotrophic lateral sclerosis. (www.maasbiolab.com).
Contact Maas BiolAB, LLC Michael Vickers, 505-843-4230